PMID- 35662614
OWN - NLM
STAT- MEDLINE
DCOM- 20220817
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 189
DP  - 2022 Jul
TI  - Metformin plus a low hypoglycemic risk antidiabetic drug vs. metformin 
      monotherapy for untreated type 2 diabetes mellitus: A meta-analysis of randomized 
      controlled trials.
PG  - 109937
LID - S0168-8227(22)00751-3 [pii]
LID - 10.1016/j.diabres.2022.109937 [doi]
AB  - AIMS: The aim of the meta-analysis of randomized controlled trials (RCTs) was to 
      compare the effectiveness of glycemic control and hypoglycemia risk of 
      combination therapy (metformin plus a low hypoglycemic risk antidiabetic drug) 
      vs. standard metformin monotherapy, in patients with untreated type 2 diabetes 
      mellitus (T2DM). METHODS: We searched PubMed, EMBASE, and Cochrane Central 
      Register of Controlled Trials through October 31, 2021 to find relevant RCTs. 
      Efficacy outcomes were changes in hemoglobulin A1c (HbA1c) and fast plasma 
      glucose (FPG) from baseline as well as proportion of patients achieving 
      HbA1c < 7%; the safety outcome was hypoglycemia risk. RESULTS: We identified 14 
      RCTs comprising 5326 patients with untreated T2DM. Mean treatment duration was 
      28.1 weeks. Pooled results showed that compared to metformin monotherapy, 
      combination therapy was associated with a reduction in HbA1c (mean difference: 
      -0.48 %, -0.58 to - 0.38) and FPG (mean difference: -0.92 mmol/L, -1.14 
      to - 0.69), and more patients achieving HbA1c < 7% (odds ratio: 2.21, 1.87 to 
      2.60). Hypoglycemic events and people experiencing hypoglycemia were not 
      different between 2 groups. CONCLUSIONS: Initial combination of metformin plus a 
      low hypoglycemic risk antidiabetic drug may achieve better glycemic control, 
      without a rise in hypoglycemia, in patients with untreated T2DM.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Hung, Wei-Tse
AU  - Hung WT
AD  - Department of Neurology, Chang Gung University College of Medicine, Chang Gung 
      Memorial Hospital, Chiayi, Taiwan.
FAU - Chen, Yuan-Jung
AU  - Chen YJ
AD  - Department of Neurology, Chang Gung University College of Medicine, Chang Gung 
      Memorial Hospital, Chiayi, Taiwan.
FAU - Cheng, Chun-Yu
AU  - Cheng CY
AD  - Department of Neurosurgery, Chang Gung University College of Medicine, Chang Gung 
      Memorial Hospital, Chiayi, Taiwan.
FAU - Ovbiagele, Bruce
AU  - Ovbiagele B
AD  - Departments of Neurology, University of California, San Francisco, California, 
      USA.
FAU - Lee, Meng
AU  - Lee M
AD  - Department of Neurology, Chang Gung University College of Medicine, Chang Gung 
      Memorial Hospital, Chiayi, Taiwan.
FAU - Hsu, Chia-Yu
AU  - Hsu CY
AD  - Department of Neurology, Chang Gung University College of Medicine, Chang Gung 
      Memorial Hospital, Chiayi, Taiwan. Electronic address: mr8898@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220601
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - *Hypoglycemia
MH  - Hypoglycemic Agents/adverse effects
MH  - *Metformin/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antidiabetic drugs
OT  - Combination therapy
OT  - Dipeptidyl peptidase-4 inhibitors
OT  - Pioglitazone
OT  - Sodium-glucose co-transporter-2 inhibitors
OT  - Type 2 diabetes mellitus
OT  - Untreated
EDAT- 2022/06/07 06:00
MHDA- 2022/08/18 06:00
CRDT- 2022/06/06 13:41
PHST- 2022/03/02 00:00 [received]
PHST- 2022/05/26 00:00 [revised]
PHST- 2022/05/28 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/08/18 06:00 [medline]
PHST- 2022/06/06 13:41 [entrez]
AID - S0168-8227(22)00751-3 [pii]
AID - 10.1016/j.diabres.2022.109937 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Jul;189:109937. doi: 10.1016/j.diabres.2022.109937. 
      Epub 2022 Jun 1.